– Investigational New Drug (IND) enabling preclinical and toxicology studies successfully completed – Initiation of a Phase 1 clinical trial of...
–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine...
– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos...
Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel...
Satellos Bioscience Inc. ouvre les marchés Canada NewsWire TORONTO, le 15 mai 2024 TORONTO, le 15 mai 2024 /CNW/ - Frank Gleeson...
Satellos Bioscience Inc. Opens the Market Canada NewsWire TORONTO, May 15, 2024 TORONTO, May 15, 2024 /CNW/ - Frank Gleeson Co-Founder and Chief...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule...
- Conducted preclinical toxicology studies and GMP manufacturing of SAT-3247 - On track to initiate Phase 1 first-in-human clinical trials...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule...
- Engaged CRO for first-in-human SAT-3247 Phase 1 clinical study - Initiated GLP toxicity studies and GMP manufacturing of SAT-3247 - Continues...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule...
- Orally administered SAT-3247 demonstrates efficacy across three mouse models of muscle degeneration - Efficacy in muscle injury model...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL), a public biotech company developing new small molecule therapeutic approaches...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.